Merck Insomnia Drug Safer at Lower Dose, FDA Staff Says

Merck & Co.’s experimental insomnia drug, designed to turn off wakefulness rather than subdue the brain into slumber like Ambien, may only be safe at lower doses than what the company has proposed, U.S. regulators said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.